Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Pfizer price target lowered to $42 from $43 at Morgan Stanley
- Merck price target lowered to $116 from $118 at Truist
- Merck announces Phase 3 KEYNOTE-A18 trial met one primary endpoint
- Johnson & Johnson Stock (NYSE:JNJ): Medicare Negotiations and Q2 Earnings in Focus
- Merck price target raised to $113 from $102 at BMO Capital